CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vizgen, Inc., the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, has achieved a significant victory in its ongoing legal battle with 10x Genomics and Harvard University. The U.S. District Court recently ruled in Vizgen’s favor, allowing Vizgen to expand its case based on new evidence uncovered during discovery in the litigation. The Court’s ruling substantially strengthens Vizgen’s position against 10x Genomics and Harvard, who must now defend against additional allegations of antitrust violations. Despite strenuous objections from 10x and Harvard, the Court approved Vizgen’s request to amend the claims to include additional antitrust allegations relating to 10x’s anticompetitive economic practices. These new allegations bolster Vizgen’s existing antitrust counterclaims against both 10x and Harvard, accusing them of conspiring to monopolize the market and obstructing Vizgen’s ability to compete globally

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vizgen, Inc., the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, announced today the issuance by the US Patent Office of a patent that covers the in situ imaging of the spatial transcriptome. U.S. Patent No. 11,959,075 is for robust multiplex imaging of RNA and its spatial organization in a sample. "This latest patent relates to our MERFISH technology and enables groundbreaking advancements in the spatial genomics landscape," said Terry Lo, CEO, Vizgen, Inc. "It is another patent underscoring Vizgen’s leadership in the field, providing the industry’s best tools for single-cell spatial biology, and driving discoveries aimed at improving human health," he said

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vizgen, Inc. the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today unveiled the MERSCOPE® Ultra Platform and MERFISH 2.0 chemistry at the AACR 2024 Annual Meeting. These powerful tools are uniquely suited to supporting basic and translational research and will be commercially available in the second half of the year. The MERSCOPE Ultra Platform is a powerful new high plex in situ spatial multiomic analysis system. MERSCOPE Ultra features the optimum combined capabilities of imaging area and throughput in a spatial transcriptomics imaging platform. The platform is capable of processing 3 cm2 of tissue on a single slide and acquires images at more than double the speed of the MERSCOPE Platform